Functional Pulmonary Capillary Surface Area in BPA for CTEPH
Recruiting
N/A
Interventional Study
Hypertension, Pulmonary
Pulmonary Thromboembolisms
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 40 (estimated)
- Sponsor
- Jewish General Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
Exclusion Criteria:
* Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,
* Presence of patent foramen ovale
Contacts